A carregar...

Neoadjuvant sipuleucel-T induces both Th1 activation and immune regulation in localized prostate cancer

Sipuleucel-T is the only FDA-approved immunotherapy for metastatic castration-resistant prostate cancer. The mechanism by which this treatment improves survival is not fully understood. We have previously shown that this treatment can induce the recruitment of CD4 and CD8 T cells to the tumor microe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncoimmunology
Main Authors: Hagihara, Katsunobu, Chan, Stephen, Zhang, Li, Oh, David Y., Wei, Xiao X., Simko, Jeffry, Fong, Lawrence
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287789/
https://ncbi.nlm.nih.gov/pubmed/30546940
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1486953
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!